Finland· FI-REL-REL61283
Cejemly
A sugemalimab product containing sugemalimab, registered in Finland by Cstone Pharmaceuticals Ireland Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sugemalimab is registered in 7 of 19 countries.
Countries holding a registration under ATC L01FF11 (sugemalimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Sugemalimab · ATC L01FF11
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Fimea (Finland)- Active substance
- Sugemalimab
- Manufacturer
- Cstone Pharmaceuticals Ireland Limited
- Country
- Finland (FI)
- ATC code
- L01FF11
- ATC class
- Sugemalimab
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sugemalimab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCejemly 600 mgSfl Pharmaceuticals Deutschland
- CzechiaCEJEMLYCStone Pharmaceuticals Ireland Limited, Dublin 1
- IrelandCejemly 600 mg concentrate for solution for infusionCstone Pharmaceuticals Ireland Limited
- IcelandCejemlyCstone Pharmaceuticals Ireland Limited
- SwedenCejemly 600 mg Koncentrat till infusionsvätska, lösningCStone Pharmaceuticals Ireland Limited
- SpainCEJEMLY 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONCstone Pharmaceuticals Ireland Limited
- NetherlandsCejemly 600 mg concentraat voor oplossing voor infusieCStone Pharmaceuticals Ireland Limited
- PolandCejemlyCStone Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cejemly
- Liechtenstein · Cejemly
- Norway · Cejemly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c185f867-17d1-4d03-9c4f-e144a5f0db38 GET /v1/drugs/c185f867-17d1-4d03-9c4f-e144a5f0db38?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "600 mg",
"atc_label": "sugemalimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1833/001",
"fimea_rel_id": "REL61283",
"authorised_at": "2024-07-24"
}See everything about sugemalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.